皮上腺癌:一个孤儿的恶意:从病人到长椅和背后
Margaret E Wierman1, Katja Kiseljak Vassiliades
1Aurora, Colorado.
概括
开发了新的上腺皮质癌 (ACC) 研究模型,包括细胞系和患者衍生的异种移植. 这些模型将加速对这种罕见癌症的新疗法的发现.
科学领域:
- 在瘤学瘤学.
- 癌症研究 癌症研究
- 内分泌学 在内分泌学.
背景情况:
- 皮上腺癌 (ACC) 是一种罕见的内分泌恶性瘤,预后不佳,治疗选择有限.
- 目前的疗法,包括唯一的FDA批准的药物米托坦,提供边际生存益处与显著的毒性.
- 推动ACC治疗的一个关键障碍是缺乏有效的临床前研究模型.
研究的目的:
- 开发和描述人类新型上腺皮癌的体外和体内临床前模型.
- 为药物发现和机制研究建立新的ACC细胞系和患者衍生异种移植 (PDX).
- 促进对ACC的新治疗策略和组合的测试.
主要方法:
- 产生了两个新的人类上腺皮癌细胞系 (CU-ACC1和CU-ACC2).
- 开发了十个患者衍生异种移植 (PDX) 模型和两个人性化的ACC-PDX模型.
- 这些模型用于全球研究合作的分发.
主要成果:
- 成功建立并描述了新的ACC细胞系和PDX模型.
- 这些模型代表了各种ACC亚型,并允许进行体外和体内研究.
- 有模型可用于测试新疗法,包括与免疫疗法结合,并检查米托坦的机制.
结论:
- 新开发的ACC临床前模型对于推动这种孤儿癌症的研究至关重要.
- 这些模型将能够识别新的治疗点,并测试创新的治疗方法.
- 预计这笔资金将加速开发更有效的上腺皮癌患者治疗方法的进展.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.7K
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
1.8K
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
